pleas
see
addit
file
translat
abstract
six
offici
work
languag
unit
nation
recent
outbreak
human
zair
ebolaviru
ebov
infect
start
west
african
countri
result
infect
patient
novemb
total
death
report
six
affect
countri
guinea
liberia
mali
sierra
leon
spain
unit
state
america
two
previous
affect
countri
nigeria
seneg
apart
support
care
neither
licens
vaccin
specif
therapi
avail
treatment
human
ebov
infect
world
health
organ
consid
ethic
accept
offer
unproven
intervent
shown
promis
result
laboratori
anim
model
yet
evalu
safeti
efficaci
human
potenti
sourc
treatment
prevent
sever
promis
therapeut
agent
identifi
treatment
immun
ebov
may
includ
monoclon
antibodi
mab
base
therapi
eg
zmapp
antisens
phosphorodiamid
morpholino
oligom
pmo
lipid
nanoparticl
small
interf
rna
lnpsirna
tkmebola
ebov
glycoproteinbas
vaccin
use
liveattenu
recombin
vesicular
stomat
viru
rvsvebogp
chimpanze
adenoviru
rchadebogp
base
vector
human
trial
result
agent
would
avail
next
year
moreov
exist
suppli
experiment
medic
vaccin
compassion
use
either
extrem
limit
exhaust
combat
unpreced
global
publichealth
crisi
experiment
agent
avail
altern
avail
intervent
target
differ
step
replic
cycl
ebov
explor
manag
human
ebov
infect
conting
prepar
intern
dissemin
ebov
outbreak
west
africa
review
current
avail
therapeut
agent
shown
effect
suppress
prolifer
ebov
cell
cultur
anim
studi
propos
therapeut
regimen
supplement
current
support
therapi
aim
reduc
viral
load
import
factor
determin
mortal
viral
load
suppress
may
abl
prolong
patient
surviv
order
provid
better
chanc
patient
develop
natur
immun
defens
ebov
ebov
envelop
filament
rna
viru
belong
famili
filovirida
linear
nonseg
negativesens
singlestrand
rna
genom
ebov
encod
seven
structur
protein
two
nonstructur
protein
follow
order
within
genom
noncod
region
leader
nucleoprotein
np
virion
protein
glycoprotein
rnadepend
rnapolymeras
protein
lpolymeras
noncod
region
ebov
genom
encod
one
transmembran
protein
two
secret
nonstructur
protein
secretari
glycoprotein
sgp
small
solubl
glycoprotein
ssgp
small
solubl
delta
peptid
secret
ebovinfect
cell
carboxyltermin
cleavag
sgp
produc
transcript
rna
edit
precursor
amino
acid
polyprotein
posttransl
cleav
furin
two
disulfidelink
subunit
surfac
subunit
membranespan
subunit
contain
receptorbind
domain
rbd
host
cell
attach
mucinlik
domain
protect
rbd
humor
cellmedi
immun
rbd
respons
receptor
bind
viral
entri
cellular
tropism
cover
heavili
glycosyl
glycan
cap
transmembran
contain
helic
heptadrepeat
region
transmembran
anchor
cytoplasm
tail
drive
fusion
viral
membran
endosom
membran
target
cell
heterodim
assembl
trimer
viral
surfac
homotrimer
complex
form
spike
envelop
membran
matur
viral
particl
process
unstabl
abund
amount
solubl
nonvirion
form
scanti
amount
releas
circul
virusassoci
solubl
glycoprotein
releas
viru
infect
respons
primari
target
cell
activ
highli
glycosyl
mucinlik
region
cytotox
host
cell
shed
soubl
protein
due
cleavag
ebov
glycoprotein
surfac
ebovinfect
cell
tumor
necrosi
factoralpha
convert
enzym
tace
activ
noninfect
dendrit
cell
macrophag
induc
cytokin
dysregul
endotheli
cell
dysfunct
ebov
abl
counter
interferon
ifn
induc
antivir
protein
tetherin
restrict
bud
progeni
viral
particl
infect
cell
sgp
produc
nonedit
mrna
speci
furin
cleavag
precursor
presgp
sgp
share
ntermin
amino
acid
differ
carboxyl
terminu
amino
acid
sgp
releas
circul
form
homodim
antiparallel
orient
evad
antibodyassoci
innat
immun
respons
sgp
antiinflammatori
function
impair
transmigr
activ
neutrophil
particleassoci
form
mediat
endotheli
cell
activ
decreas
endotheli
cell
barrier
function
sgp
protect
endotheli
cell
cytokineinduc
barrier
dysfunct
sgp
constitut
greater
total
gp
synthes
infect
henc
hypersecret
sgp
may
protect
ebov
host
humor
immun
defens
host
endotheli
cell
cytokineinduc
cytotox
earli
phase
ebov
infect
releas
ebovinfect
cell
join
cathepsin
integrin
inhibit
entri
ebov
dosedepend
manner
prevent
superinfect
ebovinfect
cell
inhibit
entri
marburgvirus
ebov
indic
might
interfer
common
pathway
use
filovirus
gain
entri
target
cell
ssgp
yet
undefin
function
produc
transcript
edit
secret
form
disulfidelink
homodim
exclus
nglycosyl
ssgp
appear
share
similar
structur
properti
sgp
appear
antiinflammatori
function
sgp
ebov
rna
viru
limit
code
capac
util
host
uniqu
metabol
pathway
viral
entri
replic
egress
entri
ebov
cell
initi
interact
viral
host
cell
surfac
tcell
immunoglobulin
mucin
domain
receptor
upon
receptor
bind
ebov
intern
endosom
primarili
via
macropinocytosi
within
acidifi
endosom
compart
host
cell
heavili
glycosyl
cleav
smaller
fusogen
form
low
phdepend
cellular
proteas
cathepsin
l
catl
b
catb
expos
residu
receptor
bind
site
allow
bind
cholesterol
transport
niemannpick
step
late
endosom
phase
essenti
virushost
membran
fusion
viral
entri
cell
function
biochem
disrupt
cell
lack
show
resist
ebov
infect
cell
subject
diseas
resist
ebov
defect
protein
complet
fusion
viral
host
endosom
membran
via
conform
chang
viral
rna
associ
protein
releas
host
cell
cytoplasm
insid
cytoplasm
host
cell
ebov
suppress
innat
immun
respons
via
protein
hijack
transcript
translat
robust
genom
replic
product
new
virion
ribonucleoprotein
rnp
complex
mediat
transcript
replic
ebov
genom
compris
np
l
protein
essenti
initi
ebov
transcript
requir
viral
replic
howev
dynam
phosphoryl
import
mechan
regul
balanc
transcript
replic
process
ebov
replic
cycl
uniqu
properti
allow
develop
genet
stabl
delet
ebov
vaccin
protect
efficaci
mice
guinea
pig
model
matrix
protein
associ
viral
lipid
coat
import
viru
structur
stabil
matrix
protein
contribut
regul
viral
genom
replic
transcript
bud
viru
import
step
prior
viral
egress
distinct
replic
cycl
ebov
serv
attract
target
develop
therapeut
agent
ebov
see
figur
tabl
human
ebov
hemorrhag
fever
character
uncontrol
viral
replic
togeth
immun
vascular
dysregul
case
fatal
rate
type
alphabeta
interferon
encod
singl
homolog
gene
human
repres
essenti
element
host
defens
viru
infect
includ
ebov
human
ebov
infect
associ
robust
plasma
concentr
greatli
exceed
observ
viral
limit
product
ebov
protect
host
interferon
respons
encod
protein
produc
heavi
viral
load
cytopath
damag
cytokin
dysregul
human
effici
product
replic
ebov
insid
monocyt
macrophag
lead
massiv
releas
proinflammatori
cytokineschemokin
reactiv
oxygen
speci
ro
turn
lead
diffus
endotheli
cell
dysfunct
dissemin
intravascular
coagul
vasomotor
collaps
infect
antigen
present
dendrit
cell
profound
bystand
apoptosi
lymphocyt
impair
develop
adapt
immun
ebovspecif
well
cell
import
clearanc
protect
ebov
infect
infect
monocytederiv
dendrit
cell
impair
secret
proinflammatori
cytokin
upregul
costimulatori
molecul
stimul
cell
number
cell
substanti
reduc
fatal
human
nonhuman
primat
nhp
infect
death
ebov
abl
counteract
humor
cellmedi
immun
sgp
overexpress
matur
plasma
membran
result
mask
antigen
epitop
shield
mhci
integrin
lead
evas
antivir
immun
steric
shield
surfac
epitop
heavili
glycosyl
gp
impair
recognit
kill
ebovinfect
cell
natur
killer
cytotox
cell
acut
viral
infect
may
also
contribut
persist
infect
natur
reservoir
host
perpetu
spread
ebov
sgp
evad
host
antibodymedi
respons
antigen
subvers
elicit
nonneutr
antibodi
crossreact
thu
massiv
secret
sgp
ebov
may
prevent
effect
neutral
viru
ebov
infect
reduc
effect
vaccin
reli
upon
neutral
antibodi
respons
antibodi
may
lead
enhanc
infect
ebov
via
interact
complement
compon
phenomenon
known
antibodydepend
enhanc
ebov
initi
infect
bind
specif
human
receptor
site
surfac
human
cell
interact
enhanc
bind
virusantibodi
complex
ligand
cell
surfac
promot
interact
ebov
receptor
infectivityenhanc
antibodi
viru
speci
specif
primarili
correl
immunoglobulin
igm
level
level
presenc
infectivityenhanc
antibodi
ebov
infect
rais
concern
effect
gpbase
ebov
vaccin
use
passiv
prophylaxi
treatment
gpbase
antibodi
antibodi
ebov
neutral
enhanc
nonneutr
nonenhanc
neutral
antibodi
produc
infect
ebov
rel
low
frequenc
antiebov
antibodi
known
neutral
vitro
protect
vivo
wherea
antibodi
known
protect
anim
model
vivo
neutral
vitro
investig
antigp
antibodi
ebov
show
nonneutr
antibodi
recogn
gp
epitop
sgp
nonessenti
mucinlik
domain
neutral
antibodi
specif
rbd
conformationdepend
epitop
base
spike
meet
two
neutral
antibodi
recogn
conformationdepend
epitop
compris
residu
identifi
quit
distinct
mechan
neutral
human
recombin
neutral
antibodi
deriv
human
survivor
natur
ebov
infect
outbreak
kikwit
democrat
republ
congo
impair
recognit
sgp
bind
depend
presenc
residu
present
sgp
abl
inhibit
cathepsin
cleavag
monkey
deriv
neutral
monoclon
antibodi
ebov
recogn
cleav
fusionact
form
gp
mice
deriv
monoclon
antibodi
neutral
sudan
ebov
prevent
conform
chang
requir
membran
fusion
recogn
epitop
base
trimer
indic
overlap
epitop
may
one
key
site
neutral
ebov
thu
target
immunotherapi
key
goal
vaccin
design
antibodi
subclass
may
anoth
import
factor
protect
ebov
isotyp
may
offer
effect
protect
ebov
although
fulli
protect
guinea
pig
infect
fail
slow
viral
replic
protect
nhp
ebov
infect
contrast
rvsvebogp
rchadebogp
base
vaccin
demonstr
prophylact
postexposur
protect
nhp
previous
attribut
protect
action
ebovspecif
tcell
respons
induc
vaccin
limit
infect
inabl
complet
block
entri
ebov
cell
subsequ
explos
replic
rchadebogpbas
vaccin
abl
gener
potent
humor
cellmedi
respons
signific
antibodi
titer
detect
week
post
vaccin
cellmedi
immun
shown
play
critic
role
protect
ebov
infect
nhp
rchadebogpbas
vaccin
hand
humor
rather
cellmedi
respons
contribut
protect
ebov
infect
nhp
rvsvebogpbas
vaccin
candid
vaccin
express
ebov
gp
np
protect
rodent
nhp
lethal
ebov
infect
humor
cellmedi
immun
respons
work
togeth
provid
protect
lethal
ebov
infect
either
respons
alon
may
abl
limit
viru
replic
arm
immun
respons
requir
clear
infect
vp
protein
poor
induc
cellmedi
immun
inaccess
protect
effect
vpinduc
neutral
antibodi
found
surfac
virion
infect
cell
howev
genet
site
intern
protein
suscept
sirna
pmo
interfer
tkmebola
sirna
target
lpolymeras
administ
intraven
subcutan
lyophil
lipid
nanoparticl
formul
tkmebola
offer
postexposur
protect
ebov
infect
nhp
fda
approv
expand
access
program
use
tkmebola
patient
confirm
suspect
infect
antisens
phosphorodiamid
morpholino
oligom
effect
reduc
viral
load
diminish
virallyinduc
patholog
improv
surviv
nhp
ebov
infect
target
mrna
judici
placement
posit
charg
drug
backbon
drug
abl
bind
neg
charg
viru
even
bind
one
drugviru
base
pair
lost
mutat
integr
dual
target
charg
complement
significantli
lower
likelihood
drug
resist
viral
mutagenesi
issu
consensu
statement
use
whole
blood
therapi
convalesc
blood
serum
need
consid
matter
prioriti
recent
ebov
outbreak
west
african
countri
develop
neutral
antibodi
tcell
respons
import
recoveri
ebov
infect
patient
abl
mount
immun
respons
ebov
begin
recov
seven
ten
day
start
period
prolong
convalesc
survivor
earli
increas
level
igg
direct
mainli
np
follow
clearanc
circul
viral
antigen
activ
cytotox
cell
contrast
fatal
infect
character
impair
humor
respons
absent
specif
igg
bare
detect
igm
convalesc
blood
shown
improv
surviv
ebovinfect
patient
outbreak
kikwit
immun
ebov
gp
suffici
protect
individu
infect
sever
vaccin
base
ebov
gp
develop
includ
recombin
adenoviru
parainfluenza
viru
venezuelan
equin
enceph
viru
vesicular
stomat
viru
viruslik
particl
neutral
human
monoclon
antibodi
abl
protect
mous
guinea
pig
lethal
ebov
howev
protect
achiev
treatment
shortli
viral
infect
ebov
rapidli
mutat
produc
antibodyescap
mutant
henc
antibodi
therapi
may
requir
hyperimmun
polyclon
serum
panel
monoclon
antibodi
differ
epitop
specif
success
studi
laid
foundat
subsequ
clinic
research
develop
monoclon
antibodi
util
monoclon
antibodi
cocktail
zmab
zmapp
treatment
ebov
infect
nhp
interest
note
three
monoclon
antibodi
cocktail
includ
one
antibodi
bind
close
glycan
cap
two
three
monoclon
antibodi
cocktail
includ
least
one
antibodi
bind
interfac
indic
two
region
may
especi
import
protect
ebov
treatment
window
monoclon
antibodi
therapi
extend
coadministr
adenovirusvector
interferon
therapi
guinea
pig
model
monoclon
antibodi
combin
adenovirusvector
interferon
given
three
day
infect
result
surviv
signific
improv
either
treatment
alon
subsequ
studi
show
combin
therapi
capabl
save
ebovinfect
nhp
initi
presenc
detect
viremia
along
symptom
favipiravir
broadspectrum
inhibitor
viral
rna
polymeras
abl
inhibit
replic
mani
rna
virus
regist
japan
treatment
influenza
viru
infect
favipiravir
abl
suppress
replic
ebov
cell
cultur
favipiravir
initi
day
ebov
infect
induc
rapid
viru
clearanc
reduc
biochem
paramet
diseas
sever
prevent
lethal
outcom
mice
lack
type
interferon
receptor
oral
favipiravir
taken
twice
daili
day
abl
give
protect
aerosol
ebov
infect
immunedefici
mice
model
surviv
benefit
suboptim
nhp
one
six
anim
test
surviv
studi
use
dosag
two
five
time
higher
durat
longer
shown
influenza
studi
conduct
human
ebov
infect
synthet
adenosin
analogu
viral
rna
polymeras
inhibitor
function
activ
ebov
marburg
viru
rodent
cell
cultur
complet
protect
nhp
marburg
viru
infect
administ
late
hour
infect
antimalari
drug
chloroquin
abl
increas
endosom
ph
acid
endosom
environ
import
phdepend
activ
cystein
proteas
catb
catl
proteas
respons
cleavag
ebov
essenti
endosom
virushost
membran
fusion
howev
proteolyt
process
ebov
glycoprotein
demonstr
critic
ebov
replic
cell
cultur
nhp
recent
studi
use
catb
catl
defici
mous
model
studi
ebov
infect
demonstr
catb
catl
activ
absolut
requir
ebov
replic
ebov
glycoprotein
cleavag
seem
mediat
broader
spectrum
proteas
make
therapeut
approach
target
limit
proteas
unlik
benefici
combat
ebov
infect
broadspectrum
small
molecul
target
catl
cleavag
ebov
inhibit
entri
wide
varieti
virus
recent
identifi
examin
potenti
develop
potent
broadspectrum
antivir
medic
multipl
cation
amphiphil
includ
amiodaron
dronedaron
verapamil
clomiphen
toremifen
identifi
potent
inhibitor
entri
ebov
fashion
amiodaron
use
treatment
atrial
fibril
ventricular
cardiac
arrhythmia
induc
lipidosi
featur
similar
niemannpick
c
diseas
amiodaron
dronedaron
basic
pka
high
water
solubl
acid
ph
accumul
within
late
endosom
compart
block
fluidphas
endocytosi
proteolysi
lipid
traffick
induc
niemannpick
clike
phenotyp
contrast
niemannpick
typec
diseas
allevi
cholesterol
remov
amiodaron
concentr
routin
reach
human
serum
antiarrhythm
therapi
potent
inhibitor
filoviru
cell
entri
late
endosom
ebov
induc
niemannpick
clike
phenotyp
signific
inhibit
observ
endotheli
epitheli
cell
eg
macrophag
monocyt
vascular
endotheli
cell
except
primari
hepatocyt
fibroblast
inhibitori
effect
amiodaron
entri
ebov
dosedepend
revers
upon
remov
drug
prolong
exposur
amiodaron
lead
compensatori
chang
host
cell
similar
inhibitori
properti
observ
amiodaronerel
agent
dronedaron
ltype
calcium
channel
blocker
verapamil
clomiphen
toremifen
antiebov
activ
vero
interferondefici
african
green
monkey
kidney
epitheli
cell
human
hepatocellular
carcinoma
cell
line
antiebov
activ
clomiphen
toremifen
depend
estrogen
receptor
antagonist
action
upon
abil
drug
induc
niemannpick
clike
phenotyp
inhibit
viral
entri
late
endosom
clomiphen
toremifen
disrupt
interact
prime
mediat
entri
block
indirectli
target
endosomallysosom
protein
involv
cholesterol
uptak
pathway
whose
function
may
regul
clomiphen
toremifen
mgkg
everi
day
shown
result
surviv
rate
respect
ebovinfect
mice
compar
mortal
control
group
vivo
murin
ebov
infect
model
effect
male
femal
mice
howev
therapeut
dose
ebov
achiev
oral
clomiphen
dose
use
induc
ovul
human
therapeut
dose
ebov
toler
side
effect
achiev
toremifen
oral
dose
use
human
trial
treatment
advanc
carcinoma
breast
toremifen
well
absorb
bound
plasma
protein
toremifen
undergo
extens
liver
metabol
enterohepat
recircul
major
toremifen
dose
excret
metabolit
fece
long
termin
halflif
oral
toremifen
may
due
plasma
protein
bind
enterohepat
recircul
interferoninduc
transmembran
protein
ifitm
express
basal
absenc
ifn
induct
primari
tissu
cell
line
ifitm
abl
inhibit
entri
virus
host
cell
cytoplasm
permit
endocytosi
prevent
subsequ
viral
fusion
releas
viral
content
cytosol
human
ifitm
locu
locat
chromosom
compos
four
function
gene
pseudogen
virus
restrict
ifitm
protein
tend
fuse
host
cell
membran
late
endosom
lysosom
preced
induct
type
ifn
infect
cell
viral
escap
restrict
ifitm
protein
could
challeng
antagon
inhibitori
factor
function
later
stage
viru
life
cycl
opportun
de
novo
synthesi
viral
inhibitor
avail
four
human
ifitm
protein
induc
robustli
type
type
ii
ifn
activ
multipl
virus
includ
ebov
hepat
c
virus
abl
induc
interferoninduc
transmembran
protein
product
restrict
entri
ebov
earli
postexposur
treatment
significantli
increas
surviv
time
rhesu
macaqu
infect
lethal
dose
ebov
although
alon
fail
alter
mortal
rate
treatment
associ
trend
toward
lower
plasma
tissu
viral
burden
proinflammatori
cytokin
product
amilorid
deriv
use
potassiumspar
diuret
treat
hypertens
congest
heart
failur
apart
inhibit
epitheli
na
channel
cellular
nak
exchang
drug
could
also
affect
function
less
welldefin
ionexchang
disturb
equilibrium
ion
entri
ebov
host
cell
first
step
infect
crucial
determin
pathogen
upon
receptor
bind
host
receptor
ebov
intern
endosom
primarili
via
macropinocyt
pathway
amilorid
abl
inhibit
uptak
mani
virus
util
macropinocyt
pathway
host
cell
entri
amilorid
noncytotox
dosag
lead
potent
dosedepend
inhibit
entri
infect
ebov
amilorid
lead
dosedepend
inhibit
rna
synthesi
may
due
direct
blockag
nucleotid
entri
tunnel
catalyt
site
due
effect
equilibrium
essenti
cofactor
polymeras
activ
nucleotid
insert
novel
antivir
mechan
amilorid
may
uncov
new
target
drug
discoveri
ebov
adenosin
triphosph
atp
essenti
multipl
step
replic
cycl
mani
virus
nakatpas
pump
locat
plasma
membran
anim
cell
maintain
cell
membran
potenti
bud
envelop
virus
complex
phenomenon
requir
concert
action
mani
viral
host
compon
atp
may
affect
multipl
step
bud
process
atp
requir
assembl
matur
number
envelop
virus
influenza
viru
vaccinia
viru
retroviru
herp
simplex
viru
nakatpas
pump
inhibitor
ouabain
lanatosid
c
strophanthidin
digoxin
abl
inhibit
replic
influenza
viru
newcastl
diseas
viru
vesicular
stomat
viru
interferonindepend
mechan
digoxin
lanatosid
c
shown
inhibit
vaccinia
viru
replic
noncytotox
dose
ouabain
shown
antivir
activ
influenza
viru
herp
simplex
viru
sendai
viru
murin
leukem
viru
cytomegaloviru
porcin
reproduct
respiratori
syndrom
viru
human
cytomegaloviru
viru
one
common
featur
share
virus
possess
lipid
envelop
ebov
envelop
filament
rna
viru
secondari
matrix
protein
role
evas
host
immun
respons
nucleocapsid
format
regul
import
role
viral
bud
egress
nakatpas
detect
close
interact
ebov
replic
ouabain
noncytotox
concentr
abl
suppress
replic
ebov
human
cell
among
three
cardiac
glycosid
may
includ
digoxin
digitoxin
ouabain
digoxin
commonli
use
clinic
practic
ouabain
poor
oral
avail
use
primarili
research
tool
research
conduct
investig
whether
digoxin
nakatpas
inhibitor
might
play
role
manag
ebov
envelop
viru
infect
virusassoci
glycoprotein
respons
activ
human
macrophag
highli
glycosyl
mucinlik
region
subunit
cytotox
host
cell
mucinlik
region
lead
accumul
endoplasm
reticulum
induc
endoplasm
reticulum
stress
activ
nuclear
factor
kappa
b
mutat
ebov
lead
enhanc
accumul
endoplasm
reticulum
significantli
cytotox
wildtyp
viru
human
cell
accumul
protein
endoplasm
reticulum
lead
endoplasm
reticulum
overload
respons
eroverload
activ
product
ro
major
transcript
factor
antivir
immun
stimulatori
activ
thought
play
import
role
induct
proinflammatori
molecul
tumor
necrosi
factor
upon
cellular
respons
viru
infect
cytokin
dysregul
ebov
involv
massiv
ro
activ
effect
antioxid
therapi
ebov
infect
indic
import
ro
pathogenesi
ebov
activ
eroverload
rosdepend
cytokin
dysregul
novel
pneumonia
shown
suppress
highdos
nacetylcystein
nac
antioxid
therapi
mgkg
continu
infus
daili
given
poor
oral
avail
nac
rang
human
therapeut
dose
nac
equival
intraven
rout
hardli
deliv
oral
prepar
nac
categori
b
drug
pregnanc
afford
wide
therapeut
window
nac
establish
safeti
profil
even
high
dose
prolong
use
human
cytokin
dysregul
common
featur
ebov
infect
associ
enhanc
mortal
antivir
medic
direct
mutabl
viral
determin
ebov
directli
prevent
cytokin
dysregul
earli
endotheli
vascular
damag
characterist
ebov
infect
direct
effect
virusinduc
cytolysi
endotheli
cell
due
cytokin
dysregul
result
massiv
releas
proinflammatori
cytokineschemokin
ro
infect
macrophag
monocyt
lymphocyt
resist
ebov
infect
cytokin
dysregul
may
also
contribut
diffus
bystand
apoptosi
lymphocyt
safeti
profil
nac
therapeut
efficaci
highdos
nac
antioxid
therapi
manag
ebovinduc
cytokin
dysregul
confirm
may
revamp
futur
manag
ebov
infect
desper
need
viabl
treatment
regimen
africa
engend
hope
encourag
peopl
symptom
close
contact
seek
medic
treatment
limit
spread
diseas
also
help
recruit
maintain
adequ
medic
staff
high
risk
contract
diseas
propos
regimen
human
ebov
infect
base
avail
medic
inform
vivo
anim
test
vitro
cell
cultur
attach
see
tabl
regimen
contain
cocktail
current
avail
medic
target
differ
step
replic
cycl
ebov
aim
suppress
viral
prolifer
shown
viral
load
major
contribut
surviv
human
anim
studi
viral
load
suppress
may
abl
prolong
patient
surviv
order
allow
develop
natur
bodi
immun
defens
ebov
ebov
undergon
rapid
mutat
spread
human
ebov
rna
viru
replic
highli
error
prone
nearli
one
viral
mutat
occur
cycl
replic
extrem
high
mutat
rate
lead
signific
genet
antigen
divers
allow
ebov
popul
evolv
resist
antivir
medic
vaccin
combin
therapi
use
treatment
rna
viru
infect
human
immunodefici
viru
hiv
hepat
c
minim
develop
drug
resist
given
broad
cell
tropism
high
replic
rate
ebov
due
potent
suppress
innat
adapt
immun
respons
host
patient
ebov
infect
extrem
high
viral
load
select
pressur
presenc
high
mutat
rate
viral
load
human
ebov
infect
make
evolut
ebov
viral
strain
resist
singl
drug
inevit
current
avail
medic
propos
treatment
regimen
contain
cocktail
antivir
medic
target
differ
step
ebov
replic
order
achiev
maxim
suppress
viral
replic
prevent
rapid
develop
resist
favipiravir
drug
regimen
direct
mutabl
target
shown
reduc
replic
ebov
current
ebov
vaccin
rvsvebogp
rchadebogp
therapeut
agent
zmapp
tkmebola
pmo
favipiravir
develop
direct
mutabl
target
ebov
effect
limit
viral
mutat
ebov
rna
viru
limit
code
capac
util
host
uniqu
metabol
pathway
viral
entri
replic
egress
therapeut
agent
current
review
direct
nonmut
target
host
independ
viral
mutat
medic
fdaapprov
treatment
diseas
avail
stockpil
immedi
use
may
also
complementari
role
therapeut
agent
develop
direct
mutabl
target
ebov
primari
target
ebov
mononuclear
phagocyt
system
spectrum
target
cell
increas
includ
endotheli
cell
fibroblast
hepatocyt
mani
cell
advanc
stage
diseas
ebov
may
produc
viral
load
virion
per
ml
serum
termin
ill
patient
oral
amiodaron
prophylaxi
induc
niemannpick
clike
phenotyp
cell
mononuclear
phagocyt
system
may
prevent
viral
entri
cell
needl
stick
injuri
protect
mononuclear
system
prophylaxi
cocktail
therapi
hope
offer
better
chanc
surviv
patient
allow
develop
natur
bodi
immun
defens
ebov
infect
liver
contain
largest
number
fix
tissu
macrophag
kupffer
cell
part
reticuloendotheli
immun
defens
system
bodi
major
target
ebov
infect
ebov
replic
high
titer
liver
hepat
apoptosi
may
play
role
pathogenesi
ebov
infect
toremifen
ad
treatment
regimen
hepat
protect
amiodaron
exert
inhibitori
action
ebov
hepatocyt
howev
amiodaron
toremifen
increas
qtc
risk
torsad
de
point
therefor
electrocardiogram
care
monitor
drug
use
amiodaron
favipiravir
toremifen
avail
stockpil
oral
prepar
properti
advantag
outbreak
situat
conting
plan
potenti
ebov
epidem
pandem
avoid
intraven
administr
prevent
needl
stick
injuri
healthcar
worker
care
infect
patient
may
potenti
adjunct
postexposur
therapi
highrisk
exposur
needl
stick
injuri
induc
limit
entri
ebov
postexposur
treatment
associ
trend
toward
lower
plasma
tissu
viral
burden
proinflammatori
cytokin
product
reduct
viral
load
cytokin
dysregul
coupl
optim
support
therapi
may
improv
chanc
surviv
host
allow
develop
natur
immun
control
underli
ebov
infect
activ
multipl
virus
includ
ebov
hepat
c
interferon
induc
play
import
role
treatment
human
hcv
infect
inhibit
entri
hcv
host
cell
six
million
intern
unit
miu
intraven
administr
effect
three
miu
twicedaili
regimen
treatment
hcv
infect
lesser
side
effect
requir
discontinu
medic
aim
therapi
regimen
post
needl
stick
prophylaxi
ebov
infect
induc
limit
viral
entri
dose
post
needl
stick
prophylaxi
induct
therapi
hcv
infect
human
chosen
infect
fulli
establish
replac
convalesc
blood
serum
highdos
nac
infus
provid
passiv
humor
immun
control
rosdepend
cytokin
dysregul
respect
ebov
classifi
biosafeti
level
pathogen
classifi
center
diseas
control
prevent
categori
agent
bioterror
approv
therapi
vaccin
treatment
carri
high
potenti
largescal
dissemin
recent
polit
econom
militari
religi
turbul
around
world
rais
concern
ebov
might
use
agent
bioterror
recent
ebov
epidem
spiral
control
west
africa
contain
measur
work
past
isol
infect
trace
contact
fail
due
exponenti
rise
infect
patient
although
shortterm
three
sixweek
probabl
intern
spread
outsid
african
region
small
risk
extens
outbreak
african
countri
follow
intern
dissemin
longer
time
scale
neglig
indic
public
health
emerg
potenti
grow
extraordinarili
destruct
dimens
although
sever
promis
therapeut
agent
vaccin
ebov
undergo
phase
human
trial
current
epidem
might
outpac
speed
drug
vaccin
produc
combat
unpreced
global
publichealth
crisi
experiment
agent
avail
altern
avail
intervent
capabl
manag
enhanc
viral
replic
cytokin
dysregul
human
ebov
infect
explor
stockpil
conting
prepar
worstcas
scenario
impend
human
ebov
pandem
like
virus
ebov
larg
reli
host
cell
factor
physiolog
process
entri
replic
egress
turn
lead
cytopath
damag
cytokin
dysregul
death
host
nonmut
key
step
insid
host
may
novel
target
futur
therapeut
strategi
rapidli
mutat
virus
efficaci
amilorid
digoxin
amiodaron
highdos
nac
antioxid
therapi
human
ebov
infect
confirm
avail
afford
stockpil
agent
make
ideal
medic
pandem
situat
countri
limit
resourc
may
complementari
role
antivir
medic
prevent
emerg
resist
strain
may
also
signifi
major
breakthrough
futur
manag
ebov
infect
